The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Compounds · Other compounds

Why catalogue breadth is not evidence of anything

Under review
Under review. A claim in this topic has been challenged and a moderator has asked for a source. The status is a label, not a judgement, and it is removed when the source arrives or the claim is withdrawn.
CB
c.bakkerTL221 Jan 2026#1

Why catalogue breadth is not evidence of anything I have a specific reason for asking rather than idle curiosity, and the context is below.

What changes if the standard account of catalogue breadth is wrong? I ask because I have been treating it as settled and I noticed this week that I could not say why.

Working through the consequences rather than the evidence, since others here are better placed on the evidence.

9 likes 6mo
KA
k.asanteTL210 May 2026#2

Adding the measurement that the opening post says would settle it.

Reading a supplier's product description as a marketing document: that is exactly what it is. The hyperbole, the mechanism written as fact, the theoretical benefits stated as established benefits — all of that is marketing. Treat it as such and separate it from evidence where evidence exists.

The right answer here may simply be that it has not been measured.

0 likes 3mo
V
VPoulsenTL3Regular26 Jul 2026#3

This subcategory exists because some people will research compounds outside the main groups discussed here. The standard of evidence and honesty about its limits applies to everything discussed, not just to approved drugs.

28 likes 2d

Suggested topics

TopicParticipantsRepliesViewsActivity
Sequence verification for an obscure compound: how it is done — what changed since
On the subject in the title: Sequence verification for an obscure compound: how it is done — what changed since Working notes rather than a conclusion. What changes if the standard account of Sequence…
TNDBSOLGHF+100 108 1.3k 8mo
Research-use-only status: what it means legally and practically
Research-use-only status: what it means legally and practically Writing it up because I had to work it out twice and would rather nobody else did. Asking about research-use-only status directly, because I…
KFKLVSHVAF+72 81 44k 1d
Research-use-only status: what it means legally and practically — a second dataset
Research-use-only status: what it means legally and practically — a second dataset — setting out what I have, and where I think it stops being reliable. Posting a small dataset on Research-use-only status. It…
TWONMSRFF+109 125 2k 16mo
Melanocortin agonists: mechanism and the documented adverse profile
Melanocortin agonists: mechanism and the documented adverse profile — setting out what I have, and where I think it stops being reliable. Melanocortin agonists, and specifically the version of it that the…
APAWCEBWGR+7 11 5.5k 20mo
Coming back to: Reading a supplier's product description as a marketing document
Reading a supplier's product description as a marketing document Writing it up because I had to work it out twice and would rather nobody else did. Documentation question rather than a pharmacological one,…
HBELCVHNDN+35 39 688 5mo

Related topics — sharing the tags research use only, needs a source, custom synthesis

TopicParticipantsRepliesViewsActivity
Second pass at: Metformin co-administration and additive GI effects
On the subject in the title: Second pass at: Metformin co-administration and additive GI effects Working notes rather than a conclusion. Posting a small dataset on Metformin co-administration. It is mine, it…
ANRFAPFFRD+131 142 56k 19d
Citing a preprint in a maintained document: our rule and its reasoning
On the subject in the title: Citing a preprint in a maintained document: our rule and its reasoning Working notes rather than a conclusion. A preprint question rather than a question about the finding in it.…
OVSLTN 2 467 4mo
Common supplements people ask about, assessed one at a time — a second dataset
Posting this under the heading it deserves: Common supplements people ask about, assessed one at a time — a second dataset Everything below is what sits behind that. A follow-up question about Common…
VMJRCTDBTD+97 104 15k 3mo
Documenting a payment dispute without naming and shaming — the long version
Posting this under the heading it deserves: Documenting a payment dispute without naming and shaming — the long version Everything below is what sits behind that. A narrow question about Documenting a payment…
MAQZIL 2 32k 1mo
Reading a supplier's product description as a marketing document
On the subject in the title: Reading a supplier's product description as a marketing document Working notes rather than a conclusion. Documentation question rather than a pharmacological one, but about this…
SVTVMRZOIN+86 97 62k 8mo